IMA Active at the 2nd Annual Inhalation and Respiratory Drug Delivery Conference 2021

IMA Active is pleased to take part in the 2nd Annual Inhalation and Respiratory Drug Delivery Conference 2021, which will be held online, on September 09-10, 2021.

The conference will bring together experts from pharmaceutical, medical devices manufacturers, biotech industries, academia and regulatory agencies.

Besides sharing best practices this conference will give unique opportunity to discuss upcoming regulations and regulatory perspectives for device development for inhalation combination products, challenges of bringing respiratory products to a market, innovative new trends in aerosol science including toxicology and modelling, future directions of inhalation drug delivery research.

The conference program also features key case studies on the latest trends in inhalation devices and covers a wide spectrum of topic including nasal and drug delivery, respiratory drug products, analytics and tools and an overview of emerging trend in the inhalation market.

The key learning points of the Inhalation and Respiratory Drug Delivery Conference are:

• The challenges of developing inhalation devices and bring inhalation and respiratory drugdelivery products to the market;
• Regulatory updates;
• Overview of respiratory drug market;
• New technologies for pulmonary and nasal delivery;
• Innovative development of inhalation devices;
• Advantages for inhaled therapy;
• Inhalation and respiratory drug development;
• Respiratory drug products analytics;
• Future needs and directions in inhalation and respiratory drug delivery research.

Alessio Tarozzi, Product Manager for capsule fillers at IMA Active will give a presentation on “DPIs performance with Minima table-top capsule filler”.

When developing new pharmaceutical products in DPI form, industrial manufacturing aspects must be considered from the very beginning to shorten the scale-up and optimization of the final manufacturing process, as well as to achieve a more efficient and cost effective production. Precise micro-dosing, weight control and ease of device assembly are all issues that must be faced at an early stage. IMA draws on its extensive expertise to provide the most advanced solutions for DPI processing and assembly. Direct weight control performed in line on each single capsule or device, both before and after filling. Absence of mechanical powder compression for improved airway intake. Accurate micro-dosing and automatic feedback and adjustment.

This study investigates optimal process parameters for micro-dose DPIs achieved by the dosator technology. The process was carried out in a table-top capsule filling device (Minima, IMA) with different settings. Four types of Lactose were compared to study aerosolization behaviour of low-dose DPI products, which are of particular interest for lung administration. The study proves that a major advantage of using this technology for processing DPIs is that the dosators can be accurately adjusted without any need to compress or aspirate the powder. Maintaining the free-flowing properties of the dispended powder within the capsule better ensures the release of powder from the capsule into the inhaler when the capsule is pierced, thereby better controlling both the emitted dose and the fine particle fraction of the dose discharged from the DPI.

Subscribe now>>